ERWINASE

This brand name is authorized in Austria, Canada, Estonia, Malta, Netherlands, Poland, United Kingdom

Active ingredients

The drug ERWINASE contains one active pharmaceutical ingredient (API):

1 Asparaginase UNII G4FQ3CKY5R - ASPARAGINASE

Asparaginase hydrolyses asparagine to aspartic acid and ammonia. In contrast to normal cells, lymphoblastic tumour cells have a very limited capacity for synthesising asparagine because of a significantly reduced expression of asparagine synthetase. Therefore, they require asparagine which diffuses from the extracellular environment. As a result of asparaginase-induced asparagine depletion in serum, protein synthesis in lymphoblastic tumour cells is disturbed while sparing most normal cells. Read about Asparaginase

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01XX02	Asparaginase	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents
Discover more medicines within L01XX02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 02237815
Country: EE	Ravimiamet	Identifier(s): 1437588
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 102211
Country: MT	Medicines Authority	Identifier(s): AA565/72501
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 51519
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100335460